European Journal of Nuclear Medicine and Molecular Imaging · 2024 · 62 citations · 68 references
MedicineOncologyRadiologyDiagnostic Nuclear MedicineNeuroradiologyTheranosticsNuclear Medicine ImagingPositron Emission TomographySomatostatin Receptor ImagingTheranostic ApproachesTheranostic ImagingTheranostics In OncologyMeningioma RecurrenceMolecular Imaging TracersPositron Emission Tomography DetectionSomatostatin Receptor PetSomatostatin Receptor ScintigraphySomatostatin Receptor TargetingSomatostatin Receptor TheranosticsSomatostatin Receptor Therapy
PURPOSE: To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands. METHODS: This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). RESULTS: Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma. CONCLUSION: These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.
68
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +17
John J. Zaknun, Lisa Bodei, Jan Mueller‐Brand et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2013 · 809 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
EANO guideline on the diagnosis and management of meningiomas
Roland Goldbrunner, Pantelis Stavrinou, Michael D. Jenkinson et al. · Neuro-Oncology · 2021 · 707 citations · Full text
Medicine, Neurosurgery, Oncology +17